País: África do Sul
Língua: inglês
Origem: South African Health Products Regulatory Authority (SAHPRA)
Adcock
ADCO-CAPTOPRIL 25 mg Tablets ADCO-CAPTOPRIL 50 mg Tablets SCHEDULING STATUS: S3 PROPRIETARY NAME (and dosage form): ADCO-CAPTOPRIL 25 mg Tablets ADCO-CAPTOPRIL 50 mg Tablets COMPOSITION: Each ADCO-CAPTOPRIL 25 mg Tablet contains 25 mg Captopril Each ADCO-CAPTOPRIL 50 mg Tablet contains 50 mg Captopril PHARMACOLOGICAL CLASSIFICATION: A. 7.1 Vasodilators, Hypotensive Medicine PHARMACOLOGICAL ACTION: The pharmacological action of Captopril is thought to be primarily due to the inhibition of the Renin-Angiotensin- Aldosterone system, but since it is also effective in managing hypertension where plasma renin activity is not elevated, other mechanisms are probably also involved. Captopril inhibits the angiotensin-converting enzyme (ACE) and therefore prevents the conversion of the relatively inactive Angiotensin I to Angiotensin II which is one of the most potent endogenous vasoconstricting substances. By the inhibition of ACE there is an increase in plasma renin activity and a decrease in aldosterone concentrations in the blood and urine. This may result in slightly raised serum-potassium concentrations and salt and water loss. Captopril produces a decrease in total peripheral resistance and in patients with congestive heart failure, a reduction in both the preload and afterload. The hypotensive effect of Captopril is enhanced by diuretics and other antihypertensive agents. Captopril is rapidly absorbed after oral administration and produces maximum effect within one to two hours. Bioavailability is about 60% - 75%, however this is significantly reduced by food and thus should generally be given before meals. About 30% is bound to plasma proteins. The half-life of Captopril is two to three hours but this is increased in renal failure. INDICATIONS: ADCO-CAPTOPRIL Tablets are indicated for Leia o documento completo